research article
No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting
2011
Objective. About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable.
Type
research article
Web of Science ID
WOS:000291240700012
Author(s)
Jacob, Francis
Meier, Mara
Caduff, Rosmarie
Pochechueva, Tatiana
Hacker, Neville
Fink, Daniel
Heinzelmann-Schwarz, Viola
Date Issued
2011
Published in
Volume
121
Start page
487
End page
491
Subjects
Editorial or Peer reviewed
REVIEWED
Written at
EPFL
EPFL units
Available on Infoscience
December 16, 2011
Use this identifier to reference this record